Literature DB >> 8181320

Vasoconstrictor effects of angiotensin II on the pulmonary vascular bed.

B J Lipworth1, K D Dagg.   

Abstract

The systemic pressor effects of angiotensin II (ANGII) are well described, whereas relatively little is known regarding its effects on the pulmonary circulation in humans. Doppler echocardiographic measurements were performed in eight normal volunteers after a 30-min control infusion (baseline), after sequential 30 min stepwise infusions of ANGII (2, 4, and 6 ng/kg/min), and again 30 min after stopping ANGII therapy. There were significant dose-related increases in mean pulmonary arterial pressure and total pulmonary vascular resistance, with values returning to baseline after stopping ANGII therapy. However, the increase in vascular resistance was proportionately greater for the pulmonary compared with systemic vascular bed, and the difference was significant at all doses of ANGII. Thus, the pulmonary vasculature exhibited greater sensitivity to the vasoconstrictor effects of ANGII in comparison with the systemic vasculature.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8181320     DOI: 10.1378/chest.105.5.1360

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

1.  Characterization of the anatomical structures involved in the contractile response of the rat lung periphery.

Authors:  F G Salerno; H Kurosawa; D H Eidelman; M S Ludwig
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

2.  Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis.

Authors:  E Bruce; V Shenoy; A Rathinasabapathy; A Espejo; A Horowitz; A Oswalt; J Francis; A Nair; T Unger; M K Raizada; U M Steckelings; C Sumners; M J Katovich
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

3.  The vasorelaxing effect of hydrogen sulfide on isolated rat aortic rings versus pulmonary artery rings.

Authors:  Yan Sun; Chao-shu Tang; Hong-fang Jin; Jun-bao Du
Journal:  Acta Pharmacol Sin       Date:  2011-04       Impact factor: 6.150

4.  Genetic polymorphisms and risk for acute renal failure in preterm neonates.

Authors:  Barna Vásárhelyi; Péter Tóth-Heyn; András Treszl; Tivadar Tulassay
Journal:  Pediatr Nephrol       Date:  2004-12-31       Impact factor: 3.714

5.  Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans.

Authors:  R I Cargill; B J Lipworth
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

6.  AT1 receptor antagonist therapy preferentially ameliorated right ventricular function and phenotype during the early phase of remodeling post-MI.

Authors:  Quang T Nguyen; Federico Colombo; Robert Clement; Hugues Gosselin; Jean-Lucien Rouleau; Angelino Calderone
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

Review 7.  The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature.

Authors:  R I Cargill; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

8.  Cardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteers.

Authors:  D G Kiely; R I Cargill; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

Review 9.  ACE2, a promising therapeutic target for pulmonary hypertension.

Authors:  Vinayak Shenoy; Yanfei Qi; Michael J Katovich; Mohan K Raizada
Journal:  Curr Opin Pharmacol       Date:  2011-01-05       Impact factor: 5.547

10.  Fast relaxation and desensitization of angiotensin II contraction in the pulmonary artery via AT1R and Akt-mediated phosphorylation of muscular eNOS.

Authors:  Hae Jin Kim; Ji Hyun Jang; Yin Hua Zhang; Hae Young Yoo; Sung Joon Kim
Journal:  Pflugers Arch       Date:  2019-08-30       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.